The Major Role of Anti-Vascular Endothelial Growth Factor for Management of Macular Edema Secondary to Retinal Vein Occlusion

Document Type : Original Article

Authors

Ophthalmology department, Faculty of Medicine, Beni-Suef University, Egypt

Abstract

The goal of this study is to evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice.Macular edema is a major complication of several vascular and inflammatory retinal diseases Multiple mechanisms are implicated in its development and lead to visual impairment that could be reversible (the acute stages) or not reversible (long-standing ME). This study was conducted on 30 patients with retinal vein occlusion  .The study population were also randomly assigned into two groups regarding the management regimens: 15 subjects as central RVO ,15 subjects as branch RVO. Recently, antiangiogenic therapy with anti-vascular endothelialyy growth factor (anti-VEGF) has been used successfully to treat MO resulting from a variety of causes. As elevated intraocular levels of VEGF have been demonstrated in patients with retinal vein occlusions there is a strong basis for the hypothesis that anti-VEGF agents may be beneficial in the treatment of vascular leakage and MO.

Keywords

Main Subjects

References

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319.e1.
2. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33(5):901–910.
3. Hayreh SS, Podhajsky PA, Zimmerman MB. Central and hemicentral retinal vein occlusion: role of anti–platelet aggregation agents and anticoagulants. Ophthalmology. 2011;118(8):1603–1611.
4. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594–1602.
5. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429–437.e7.
6. Steinbrook R. The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409–1412.
7.  Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185.
8.  Song WT, Xia XB. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment. BMC Ophthalmol. 2015;15:31.
9. Wang JK. A review of randomized trials of approved pharmaceutical agents for macular edema secondary to retinal vein occlusion. Asia Pac J Ophthalmol (Phila). 2015. Epub ahead of print.
10.  Pielen A, Mirshahi A, Feltgen N, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six‐month results of a prospective randomized clinical trial. Acta Ophthalmol. 2015;93:e29‐e37.
11.  Braithwaite T, Nanji AA, Lindsley K, et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;5:CD007325.
12. Laouri M, Chen E, Looman M, et al. . The burden of disease of retinal vein occlusion: review of the literature. Eye 2011;25:981–8. 10.1038/eye.2011.92 
13. Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80–6
 

Files

Share

How to cite

Statistics